The Pfizer Oncology Together Co-Pay Savings Program for Injectables for ELREXFIO™, NIVESTYM®, NYVEPRIA™, RUXIENCE®, TRAZIMERA®, and ZIRABEV®is not valid for patients who are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medic...
As of January 1, 2025, the Pfizer Patient Assistance Program will be changing. Click here for more details Resources For Patients View Resources For Caregivers View Resources For Healthcare Providers & Office Staff View Resources With RxPathways, Pfizer has been able to make a positive impact for...
For patients who are prescribed ELREXFIO, Pfizer offers the support of Patient Access Navigators, through our Pfizer Oncology Together program, who provide personalized services for all aspects of treatment, including financial assistance resources, treatment support, and resources to nav...
We invest in innovative medicines and techniques that drive down the costs of medicine as well as patient assistance when patients can’t afford their medicines. We negotiate medicine pricing with insurers who then determine what you pay out of pocket. Our...
The official Pfizer enCompass™ site offers reimbursement & patient support services for patients treated with Pfizer Biosimilars and their healthcare providers.
For patients who are prescribed ELREXFIO, Pfizer offers the support of Patient Access Navigators, through our Pfizer Oncology Together program, who provide personalized services for all aspects of treatment, including financial assistance resources, treatment support, a...
For further assistance with reporting to VAERS call 1-800-822-7967. The reports should include the words "Pfizer-BioNTech COVID-19 Vaccine EUA" in the description section of the report. • vaccine administration errors whether or not associated with an adverse event, • serious adverse ...
Pfizer announces that it has completed the sale of its Capsugel business to an affiliate of Kohlberg Kravis Roberts & Co. L.P. (together with its affiliates, “KKR”), following the receipt of required regulatory clearances, including in the U.S. and the European Union. ...
pathways involved in disease progression. This has made them a preferred choice for personalized medicine in oncology, immunology, and rare diseases. Growing Awareness Among Stakeholders: Awareness campaigns and medical education initiatives have enhanced the understanding of the efficacy and benefits of ...
So the work for COVID happened in one of the six business units, and happened predominantly in the R&D domain of these clinical units. But at the same time the Oncology business unit and the Rare Disease business unit and the Internal Medicine business unit and all the other business units...